Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01012362 · ClinicalTrials.gov registry record · Phase 1
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT01012362 is a Phase 1 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 31 participants.
The verdict
NCT01012362, a Phase 1 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a Phase I study; dose escalating the combination of pazopanib when taken daily and ixabepilone when administered on day 1 of a 3 week treatment course.
Interventions
- DRUG Pazopanib
- DRUG Ixabepilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01012362
The ClinicalTrials.gov registry entry for NCT01012362 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pazopanib is the first listed.
NCT01012362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01012362 about?
NCT01012362 is a clinical study titled "Study of Pazopanib and Ixabepilone in Patients With Solid Tumors". This is a Phase I study; dose escalating the combination of pazopanib when taken daily and ixabepilone when administered on day 1 of a 3 week treatment course.
What is the current status of trial NCT01012362?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2009-12. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01012362?
The interventions under investigation include: Pazopanib (DRUG), Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT01012362?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.